Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials, such as cells, proteins, and nucleic acids used in biopharmaceutical manufacturing, quality control process, food safety, and science education applications. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, and transfusion and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Bio-Rad Laboratories Inc. Class A

Jefferies analyst Akash Tewari maintained a Buy rating on Crescent Biopharma today and set a price target of $35.00. According to TipRanks, Tewari ...

Jefferies Sticks to Its Buy Rating for Crescent Biopharma (CBIO)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Intuitive Surgical (ISRG – Research Report) and Cres...

Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG) and Crescent Biopharma (CBIO)

Earnings reports, analyst updates, and new economic data are behind the biggest stock market movements on Thursday.


Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BioAge Labs, Inc. (BIOA – Research Report) and Ins...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: BioAge Labs, Inc. (BIOA) and Insulet (PODD)

Crescent Biopharma stock gained on Thursday after it revealed a new collaboration and other major updates.


Why Is Crescent Biopharma Stock (CBIO) Up Today?

Piper Sandler analyst Biren Amin maintained a Buy rating on BridgeBio Pharma today and set a price target of $98.00. Amin covers the Healthcare sec...

Piper Sandler Remains a Buy on BridgeBio Pharma (BBIO)

The latest update is out from Biome Australia Ltd ( ($AU:BIO) ). Biome Australia Limited has appointed Lauren Dwyer as the new Chief Financial Offi...

Biome Australia Appoints New CFO to Drive International Expansion

An update from Biome Australia Ltd ( ($AU:BIO) ) is now available. Biome Australia Limited announced a change in the director’s interest, with Geof...

Biome Australia Director Increases Stake, Signaling Growth Confidence

Biome Australia Ltd ( ($AU:BIO) ) has shared an update. Biome Australia Limited announced the results of its Annual General Meeting, where all reso...

Biome Australia Limited Announces AGM Results with Strong Shareholder Support

Amid market volatility, technical analysis can help investors identify compelling stock opportunities. Using TipRanks’ Technical Analysis Screener,...

3 Stocks Flashing ‘Buy’ Alerts for Investors on Technical Charts

An update from Sabio Holdings ( ($TSE:SBIO) ) is now available. Sabio Holdings reported its Q3 2025 financial results, highlighting a 2% year-over-...

Sabio Holdings Reports Q3 2025 Results with Strong Branded Business Growth

Jefferies analyst Andrew Tsai maintained a Buy rating on BridgeBio Pharma today and set a price target of $85.00. Tsai covers the Healthcare sector...

Jefferies Remains a Buy on BridgeBio Pharma (BBIO)

The latest announcement is out from Sabio Holdings ( ($TSE:SBIO) ). Sabio Holdings announced it will release its unaudited fiscal Q3 2025 financial...

Sabio Holdings to Release Q3 2025 Financial Results

Zenas BioPharma, Inc. ( ($ZBIO) ) has released its Q3 earnings. Here is a breakdown of the information Zenas BioPharma, Inc. presented to its inves...

Zenas BioPharma Reports Q3 2025 Financial Results

Jade Biosciences, Inc. ( ($JBIO) ) has released its Q3 earnings. Here is a breakdown of the information Jade Biosciences, Inc. presented to its inv...

Jade Biosciences Advances Autoimmune Therapies

Fortress Biotech Inc (($FBIO)) has held its Q3 earnings call. Read on for the main highlights of the call. Fortress Biotech Inc’s recent earnings c...

Fortress Biotech’s Earnings Call Highlights EMROSI Success

The latest update is out from BioVaxys Technology ( ($TSE:BIOV) ). BioVaxys Technology Corp. has announced a debt settlement transaction with certa...

BioVaxys Announces Debt Settlement to Strengthen Financial Position

In a report released today, Austin Moeller from Canaccord Genuity maintained a Hold rating on Bioceres Crop Solutions, with a price target of $2.25...

Bioceres Crop Solutions (BIOX) Receives a Hold from Canaccord Genuity

The latest update is out from Mindbio Therapeutics Corp. ( ($TSE:MBIO) ). MindBio Therapeutics Corp. announced the results of its Phase 2B clinical...

MindBio Therapeutics Reports Phase 2B Trial Results on Microdosed LSD for Depression

Ibio Inc ( ($IBIO) ) has released its Q1 earnings. Here is a breakdown of the information Ibio Inc presented to its investors. iBio, Inc. is a prec...

iBio, Inc. Reports Q3 2025 Financial Results

An announcement from Bioceres Crop Solutions ( ($BIOX) ) is now available. On November 10, 2025, Bioceres Crop Solutions received an Acceleration N...

Bioceres Crop Solutions Faces Legal Action Over Alleged Defaults

The latest announcement is out from BioVaxys Technology ( ($TSE:BIOV) ). BioVaxys Technology Corp. announced an extension of its non-brokered priva...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BIO	$311.52	-1.94%	59.99K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BIO	$311.52	-1.9%	59.99K
3
4
5
6

BIO

BIO

Get Bio-Rad Laboratories Inc. Class A Data in Excel

Get Bio-Rad Laboratories Inc. Class A Data in Excel